Experience of aging in patients with rheumatic disease: A comparison with the general population

2012 ◽  
Vol 16 (5) ◽  
pp. 666-672 ◽  
Author(s):  
Christina Bode ◽  
Erik Taal ◽  
Gerben J. Westerhof ◽  
Lidewij van Gessel ◽  
Mart v van de Laar
Keyword(s):  
General Population ◽  
Rheumatic Disease

Risk of COVID-19 Infection and Hospitalization in Patients With Inflammatory Rheumatic Disease Compared With the General Population

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kali Chiriboga ◽  
Olivia Pipitone ◽  
Christopher Jones ◽  
Brian Greenberg ◽  
Jonathan Jones
Keyword(s):  
General Population ◽  
Rheumatic Disease ◽  
Inflammatory Rheumatic Disease

scholarly journals Tuberculosis in people with rheumatic disease in Finland 1995–2007: a nationwide retrospective register study

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Marjo Vuorela ◽  
Nina J Mars ◽  
Juha Salonen ◽  
Markku J Kauppi
Keyword(s):  
General Population ◽  
Rheumatic Disease ◽  
Medical Records ◽  
Social Insurance ◽  
Clinical Manifestations ◽  
Marginal Effect ◽  
Incidence Trends ◽  
Disease Register ◽  
Tnf Α ◽  
The Social

Abstract Objectives RA and its medication, especially TNF-α inhibitors, increase the risk of clinical tuberculosis (TB) infection. We aimed to investigate the clinical manifestations, incidence and temporal changes in TB occurring concurrently with rheumatic diseases (RDs) between 1995 and 2007. Methods We combined the register of the Social Insurance Institution of Finland and the National Infectious Disease Register to find adult patients with reimbursed DMARDs and with a TB notification between 1995 and 2007. After reviewing the medical records, we described their clinical manifestations and medications, explored TB incidence trends using Poisson regression, and compared the incidence of TB with that of the general population. Results We identified 291 patients with both TB and rheumatic disease (RD), 196 of whom had RA. Between 1995 and 2007, the incidence of TB in adult RD decreased from 58.8 to 30.0 per 100 000 (trend P < 0.001, average marginal effect −3.4/100 000 per year, 95% CI −4.4, −2.4). Compared with the general population, the incidence was ∼4-fold. Among RD patients, pulmonary TB was the most common form of TB (72.6%). Disseminated TB was present in 56 (19.6%) patients. Conclusion The incidence of TB among RD patients was ∼4-fold that of the general population, and it declined between 1995 and 2007. Disseminated TB was present in nearly 20% of patients.

scholarly journals A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples

Rheumatology ◽  
2008 ◽  
Vol 47 (10) ◽  
pp. 1559-1563 ◽  
Author(s):  
B. D. Thombs ◽  
M. Bassel ◽  
L. McGuire ◽  
M. T. Smith ◽  
M. Hudson ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
General Population ◽  
Rheumatic Disease ◽  
Systematic Comparison

Survey on rheumatic disease symptom recognition by the general population

2021 ◽  
Author(s):  
Nauan Fara ◽  
Lucrecia García Faura ◽  
Manuela Laffont ◽  
Valeria Aquino ◽  
Romina Hassan ◽  
...  
Keyword(s):  
General Population ◽  
Rheumatic Disease ◽  
Disease Symptom ◽  
Symptom Recognition

scholarly journals Patterns and Consequences of Multimorbidity in the General Population: There is No Chronic Disease Management Without Rheumatic Disease Management

2016 ◽  
Vol 69 (1) ◽  
pp. 12-20 ◽  
Author(s):  
Daniela Simões ◽  
Fábio A. Araújo ◽  
Milton Severo ◽  
Teresa Monjardino ◽  
Ivo Cruz ◽  
...  
Keyword(s):  
Chronic Disease ◽  
General Population ◽  
Disease Management ◽  
Rheumatic Disease ◽  
Chronic Disease Management

scholarly journals POS1163 CHARACTERISTICS AND OUTCOMES IN A REAL-WORLD COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH COVID-19

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 860.1-860
Author(s):  
Y. Ye ◽  
X. Yue ◽  
W. Krueger ◽  
L. Wegrzyn
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Risk Factors ◽  
General Population ◽  
Rheumatic Disease ◽  
The United States ◽  
Categorical Variables ◽  
Severe Illness ◽  
Comorbid Condition ◽  
Study Cohort

Background:While some risk factors for severe COVID-19 outcomes have been identified for the general population and patients with rheumatic diseases (1-3), what drives these outcomes in specific rheumatic disease remains unclear. In addition, these findings need to be assessed across various observational data sources to ensure external validity.Objectives:To describe the demographics, comorbidities, and severe COVID-19 outcomes among rheumatoid arthritis (RA) patients infected with SARS-CoV-2 in the United States.Methods:A large nationwide electronic health record database (Optum, Inc.) in the United States, with data range between February 1, 2020 and September 17, 2020, was used to describe the demographics, comorbidities, and severe COVID-19 outcomes of RA patients with confirmed COVID-19 diagnosis (diagnosis for COVID-19 or positive PCR or antigen test). Patients with a single diagnosis of RA (ICD-10 code) before the diagnosis of COVID-19 were included. Patients missing age or sex, under 18 years of age on COVID-19 diagnosis date, or having less than 15 months of activity prior to COVID-19 diagnosis in the data source were excluded. We described demographics, comorbidities, and severe COVID-19 outcomes, including death, hospitalization, ICU admission, and acute respiratory insufficiency (ARI) identified between 14 days prior to and 30 days after COVID-19 diagnosis. Mean and standard deviation (SD) was reported for continuous variables. For categorical variables, count (N) and proportion was reported.Results:We identified 2,948 patients diagnosed with RA and infected with SARS-CoV-2 (mean age± SD: 62 years ± 16, 77% female, 68% white). Of all identified patients, 38% were current or former smokers. For the 2,614 patients with BMI recorded, 78% were overweight or obese (mean BMI±SD: 31.2±8.3). The mean Charlson comorbidity index (CCI) was 3.6 (SD 3.2), with 87% of the study cohort having one or more comorbid condition, including hypertension (55%), type 2 diabetes (26%), COPD (20%), moderate to severe asthma (17%), coronary artery disease (17%), chronic kidney disease (13%), and heart failure (13%). Severe COVID-19 outcomes occurred in 618 (21%) patients. Among all RA patients with COVID-19, 137 patients (4.6%) experienced ARI, 484 patients (16.4%) were hospitalized (including 174 (5.9%) admitted to the ICU), and 155 patients (5.3%) died.Conclusion:Underlying medical conditions that are known or possible risk factors of severe illness from SARS-CoV-2 infection in the general population are common in this RA cohort from a large national EHR database. However, whether patients with RA are more vulnerable to severe COVID-19 outcome than the general population requires adjustment by age and other important confounders.References:[1]Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-66.[2]Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.[3]Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-50.Disclosure of Interests:Yizhou Ye Shareholder of: AbbVie Inc. and Pfizer Inc., Employee of: AbbVie Inc., Xiaomeng Yue Employee of: AbbVie Inc., Whitney Krueger Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Lani Wegrzyn Shareholder of: AbbVie Inc., Employee of: AbbVie Inc.

scholarly journals Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?

RMD Open ◽  
2021 ◽  
Vol 7 (1) ◽  
pp. e001439
Author(s):  
Cristiana Sieiro Santos ◽  
Xenia Cásas Férnandez ◽  
Clara Moriano Morales ◽  
Elvira Díez Álvarez ◽  
Carolina Álvarez Castro ◽  
...  
Keyword(s):  
General Population ◽  
Rheumatic Disease ◽  
Infection Rate ◽  
Rheumatic Diseases ◽  
Hospital Care ◽  
Biological Agents ◽  
Inflammatory Rheumatic Diseases ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

BackgroundThe recent outbreak of COVID-19 has raised concerns in the rheumatology community about the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It is not clear whether the use of biological agents may suppose a risk or protection against SARS-CoV-2 infection; however, it has been suggested that severe respiratory forms of COVID-19 occur as a result of exacerbated inflammation status and cytokine production. This prompted the use of interleukin 6 (IL-6) (tocilizumab and sarilumab) and IL-1 inhibitors (anakinra) in severe COVID-19 disease and more recently JAK1/2 inhibitor (baricitinib). Therefore, patients with rheumatic diseases provide a great opportunity to learn about the use of biological agents as protective drugs against SARS-CoV-2.ObjectivesTo estimate COVID-19 infection rate in patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) for inflammatory rheumatic diseases (RMD), determine the influence of biological agents treatment as risk or protective factors and study the prognosis of patients with rheumatic diseases receiving biological agents compared to the general population in a third-level hospital setting in León, Spain.MethodsWe performed a retrospective observational study including patients seen at our rheumatology department who received bDMARDs for rheumatic diseases between December 1st 2019 and December 1st 2020, and analysed COVID-19 infection rate. All patients who attended our rheumatology outpatient clinic with diagnosis of inflammatory rheumatic disease receiving treatment with biological agents were included. Main variable was the hospital admission related to COVID-19. The covariates were age, sex, comorbidities, biological agent, duration of treatment, mean dose of glucocorticoids and need for intensive care unit . We performed an univariate and multivariate logistic regression models to assess risk factors of COVID-19 infection.ResultsThere were a total of 4464 patients with COVID-19 requiring hospitalisation. 40 patients out of a total of 820 patients with rheumatic diseases (4.8%) receiving bDMARDs contracted COVID-19 and 4 required hospital care. Crude incidence rate of COVID-19 requiring hospital care among the general population was 3.6%, and it was 0.89% among the group with underlying rheumatic diseases. 90% of patients receiving bDMARDS with COVID-19 did not require hospitalisation. Out of the 4464 patients, 869 patients died, 2 of which received treatment with biological agents. Patients with rheumatic diseases who tested positive for COVID-19 were older (female: median age 60.8 IQR 46-74; male: median age 61.9 IQR 52-70.3) than those who were negative for COVID-19 (female: median age 58.3 IQR 48-69; male: median age 56.2 IQR 47-66), more likely to have hypertension (45% vs 26%, OR 2.25 (CI 1.18-4.27),p 0.02), cardiovascular disease (23 % vs 9.6%, OR 2.73 (1.25-5.95), p 0.02), be smokers (13% vs 4.6%, OR 2.95 (CI 1.09-7.98), p 0.04), receiving treatment with rituximab (20% vs 8%, 2.28 (CI 1.24-6.32), p 0.02) and a higher dose of glucocorticoids (OR 2.5 (1.3-10.33, p 0.02) and were less likely to be receiving treatment with IL-6 inhibitors (2.5% vs 14%, OR 0.16, (CI 0.10-0.97, p 0.03). When exploring the effect of the rest of the therapies between groups (affected patients vs unaffected), we found no significant differences in bDMARD proportions. IL-1 inhibitors, IL-6 inhibitors, JAK inhibitors and belimumab-treated patients showed the lowest incidence of COVID-19 among adult patients with rheumatic diseases. We found no differences in sex or rheumatological disease between patients who tested positive for COVID-19 and patients who tested negative.ConclusionsOverall, the use of biological disease-modifying antirheumatic drugs (bDMARDs) does not associate with severe manifestations of COVID-19. Patients with rheumatic disease diagnosed with COVID-19 were more likely to be receiving a higher dose of glucocorticoids and treatment with rituximab. IL-6 inhibitors may have a protective effect.

scholarly journals Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark

Rheumatology ◽  
2020 ◽  
Author(s):  
René Cordtz ◽  
Jesper Lindhardsen ◽  
Bolette G Soussi ◽  
Jonathan Vela ◽  
Line Uhrenholt ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Acute Respiratory Distress Syndrome ◽  
Cohort Study ◽  
General Population ◽  
Rheumatic Disease ◽  
Distress Syndrome ◽  
Tnf Inhibitor ◽  
Inflammatory Rheumatic Disease ◽  
Hospitalised Patients ◽  
Adjusted Incidence

Abstract Objectives To estimate the incidence of COVID-19 hospitalisation in patients with inflammatory rheumatic disease (IRD); in patients with rheumatoid arthritis (RA) treated with specific DMARDs; and the incidence of severe COVID-19 infection among hospitalised patients with RA. Methods A nationwide cohort study from Denmark between 1 March to 12 August 2020. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with RA; spondyloarthritis including psoriatic arthritis; connective tissue disease; vasculitides; and non-IRD individuals.Further, the incidence of COVID-19 hospitalisation was estimated for patients with RA treated respectively non-treated with TNF-inhibitors, hydroxychloroquine, or glucocorticoids.Lastly, the incidence of severe COVID-19 infection (intensive care, acute respiratory distress syndrome, or death) among hospital-admitted patients was estimated for RA and non-IRD individudals. Results Patients with IRD (n = 58,052) had an increased partially adjusted incidence of hospitalisation with COVID-19 compared with the 4.5 million people in the general population (HR 1.46, 95%CI 1.15 to 1.86) with strongest associations for patients with RA (n = 29,440, HR 1.72, 95%CI 1.29 to 2.30) and vasculitides (n = 4072, HR 1.82, 95%CI 0.91 to 3.64). There was no increased incidence of COVID-19 hospitalisation associated with TNF-inhibitor, hydroxychloroquine nor glucocorticoid use. COVID-19 admitted patients with RA had a HR of 1.43 (95% CI 0.80 to 2.53) for a severe outcome. Conclusion Patients with IRD were more likely to be admitted with COVID-19 than the general population, and COVID-19 admitted patients with RA could be at higher risk of a severe outcome. Treatment with specific DMARDs did not affect the risk of hospitalisation.

Sign in / Sign up

Export Citation Format

Share Document